Urolithin A Supplements Are Safe in Humans
Based on current evidence, urolithin A supplements do not cause harmful effects in humans and demonstrate a favorable safety profile across multiple clinical trials. 1, 2, 3
Safety Evidence from Clinical Trials
The most comprehensive safety data comes from multiple randomized controlled trials in humans:
- Doses tested: 10-1000 mg/day for durations ranging from 28 days to 4 months 1
- Population studied: 250+ healthy individuals, primarily middle-aged and older adults (ages 65-90 years) 2, 3
- Adverse events: Only mild or moderate events that were unrelated to urolithin A supplementation 1, 2
A first-in-human clinical trial specifically established that urolithin A has a favorable safety profile as its primary outcome, with bioavailability confirmed in plasma at all tested doses 3. The largest randomized clinical trial (66 participants over 4 months) found no statistical differences in adverse events between urolithin A and placebo groups 2.
Documented Biological Effects
Urolithin A supplementation produces several measurable effects without causing harm:
- Anti-inflammatory effects: Dose-dependent reduction in C-reactive protein and inflammatory markers 1, 2
- Mitochondrial health: Upregulation of mitochondrial genes and markers of autophagy 1, 3
- Muscle function: Improved muscle endurance and strength in older adults 2
- Cardiovascular biomarkers: Reduced plasma ceramides (validated CVD risk predictors) and improved cardiovascular health markers 4
Important Context
The evidence provided about gout, diabetes, calcium supplementation, and kidney stones (references 5-6) is completely unrelated to urolithin A and should be disregarded when answering this question. These guidelines discuss entirely different compounds and conditions.
Clinical Translation Status
While urolithin A shows promise across multiple systems (cardiovascular 4, neurological 7, musculoskeletal 8), most evidence remains preclinical. However, the safety profile in humans is well-established across multiple independent trials with no serious adverse events reported.
Practical Considerations
- Bioavailability: Urolithin A is effectively absorbed and reaches target tissues, including crossing the blood-brain barrier 7
- Dosing: Most human trials used 500-1000 mg/day as the effective dose range 2, 3
- Duration: Safety confirmed for continuous use up to 4 months; longer-term studies are needed 1
The current evidence strongly supports that urolithin A supplementation is safe for human consumption with no documented harmful effects in clinical trials.